Strategic Acquisition Position Athena Diagnostics as a legacy clinical diagnostics provider with a recent acquisition by Siemens Healthineers in 2023, signaling access to broader global distribution, capital, and advanced imaging/to diagnostics capabilities for joint selling opportunities.

Neurology Focus Leverage Athena’s strong emphasis on neurology and genetic testing to cross-sell integrated neurological panels, ataxia testing, and personalized medicine services to neurology clinics and hospital systems seeking expanded molecular diagnostics.

Growth Channels Target Quest Diagnostics and Thermo Fisher/Behemoth lab networks as potential distribution or collaboration partners to expand reach of Athena’s 300+ tests, leveraging existing salesforces and service contracts.

Mid-market Opportunity Athena’s mid-sized profile (50–200 employees) and revenue in the tens of millions suggests upside through scalable laboratory services, managed services, and private-label testing for regional hospital chains and independent labs.

Tech Enablement Promote data and workflow capabilities (Alteryx, Salesforce, SAP, Oracle Peoplesoft) to offer seamless order management, data analytics for outcomes, and customer success programs that reduce cycle times and improve test utilization.